Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111800 · ClinicalTrials.gov registry record · Phase 2
A New Oral Treatment For Type II Diabetes Mellitus
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 375
- Enrollment target
NCT00111800 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 375 participants.
The verdict
NCT00111800, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 375 participants
- Enrollment target
Study Summary
This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.
Interventions
- DRUG Placebo
- DRUG DEN 2.5 mg
- DRUG DEN 7.5 mg
- DRUG DEN 15 mg
- DRUG DEN 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2005-04-28 |
| Est. Completion | 2006-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111800
The ClinicalTrials.gov registry entry for NCT00111800 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00111800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00111800 about?
NCT00111800 is a clinical study titled "A New Oral Treatment For Type II Diabetes Mellitus". This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.
What is the current status of trial NCT00111800?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 375 participants. The study started on 2005-04-28. Estimated completion is 2006-07-21.
What interventions are being tested in trial NCT00111800?
The interventions under investigation include: Placebo (DRUG), DEN 2.5 mg (DRUG), DEN 7.5 mg (DRUG), DEN 15 mg (DRUG), DEN 30 mg (DRUG).
Who is sponsoring clinical trial NCT00111800?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.